Health-Related Quality of Life with Sacituzumab Govitecan in HR+/HER2− Metastatic Breast Cancer in the Phase III TROPiCS-02 Trial

    April 2024 in “ The Oncologist ”
    Hope S. Rugo, Peter Schmid, Sara M. Tolaney, Florence Dalenc, Frederik Marmé, Ling Shi, Wendy Verret, Anuj Shah, Mahdi Gharaibeh, Aditya Bardia, Javier Cortés
    TLDR Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
    The phase III TROPiCS-02 trial assessed the health-related quality of life (HRQoL) in 543 patients with HR+/HER2− metastatic breast cancer treated with sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC). SG demonstrated significant improvements in HRQoL, including better physical functioning and reduced breathlessness, compared to TPC. It also extended the time to worsening of quality-of-life measures such as global health status, fatigue, and emotional functioning. However, SG was associated with increased diarrhea and hair loss. Despite these side effects, SG's overall benefits in maintaining quality of life support its use as a preferable treatment option for this patient population.
    Discuss this study in the Community →